Advanced searches left 3/3

Alpelisib - Crossref

Summarized by Plex Scholar
Last Updated: 03 June 2022

* If you want to update the article please login/register

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer

"ALPHABET is a randomized phase III trial evaluating alpelisib + trastuzumab with or without fulvestrant in previously treated HER2-positive PIK3CA-mutated advanced breast cancer in previously treated HER2-positive HER2-mutated advanced breast cancer. " Patients in the HR-negative cohort will receive trastuzumab + alisib, and patients in the HR-positive cohort will get the same treatment as the fulvestrant. Patients in the control arms will be given trastuzumab + physician's choice chemotherapy, according to their "controlled arms patients. ".

Source link: https://doi.org/10.2217/fon-2022-0045


110-LB: Management of Alpelisib-Induced Hyperglycemia

"The PI3K/u03b1 inhibitor alpelisib is safe in advanced breast cancer but causes hyperglycemia in up to 80% of patients. " Metformin is the first-line treatment of algebra-induced hyperglycemia, according to the FDA. This is a single-center, retrospective study of new alisib users at a cancer center in 2021. 67 patients were among those who were newly diagnosed with alisib and antidiabetic drugs during the testing process. Median's exposure time to alisib was 103 days. In 48 percent of patients, Antidiabetic drugs were used, with 25 percent using 2 or more. Hyperglycemic disorder was the primary cause of altitude's decline in patients who stopped alisib. Metformin and SGLT2 inhibitors were the only antidiabetic drugs directly related to glucose reduction in multivariable testing. In comparison to nonusers, SGLT2 inhibitor users had a higher risk of DKA than nonusers. SGLT2 inhibitors are as second-line to metformin for alisib-induced hyperglycemia in alisib-induced hyperglycemia, but at a higher rate of DKA. ".

Source link: https://doi.org/10.2337/db22-110-lb


Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

"PURPOSE" is a post-mortem cancer disease that causes a mutation in PIK3CA and fibroblast growth factor receptors in a variety of cancers, including estrogen receptor-u2013positive breast cancer, bladder cancer, and endometrial cancer. We investigated the safety and preliminary effectiveness of combining the PI3Ku03b1 selective inhibitor alpha1 with the FGFR1-4 selective inhibitor infigratinib in this first-in-human combination trial. Patients with PIK3CA-mutant advanced solid tumors, with or without FGFR1-3 changes, were enrolled in the dose escalation or one of three molecular-defined dose expansion cohorts. Molecularly tailored dose increase in breast cancer and other solid tumors harboring PIK3CA mutations, alone or in combination with FGFR alterations, has uncovered sporadic responses, primarily in tumor types and genotypes that were previously unknown to be sensitivity to these agents. CONCLUSION The combination of algesib and infigratinib can be administered in single-agent doses, but long-term tolerability may be difficult due to the high rate of dose interruption or reduction. ".

Source link: https://doi.org/10.1200/po.19.00221


Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA -Altered Solid Tumors: Results From the First-in-Human Study

Patients with PIK3CA-altered advanced solid tumors developed oral alkaline in the dose-escalation phase were administered either daily or twice a day on a daily basis. Patients with PIK3CA-altered solid tumors and the PIK3CA-wild-type, epidermal growth factor receptor 2 (u2013negative breast cancer) were given alisib 400 mg once daily in the dose-expansion phase. Maximum tolerated doses of Algebra were found as 400 mg once a day and 150 mg twice a day. In 70 patients and was followed for > 24 weeks in 13 patients, stable disease was present in 58 percent; disease control in 80 patients was 58. 2%. The median progression-free survival was 5. 5 months in patients with estrogen receptoru2013positive/human epidermal growth factor receptor 2 (u2013negative breast cancer). "British PT3CA-mutant tumors" were published in the scientific journal and encouraging preliminary use in patients with PIK3CA-aborted solid tumors, supporting the need for selective PI3K3CA-mutant tumor therapy in combination with other agents.

Source link: https://doi.org/10.1200/jco.2017.72.7107


A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

"Abstract Background Acquitted resistance to approved tyrosine kinase inhibitors limits their use in patients with gastrointestinal stromal tumors. phosphatidylitol 3-kinase inhibitor used in combination with imatinib in patients with advanced GIST who had failed prior therapy with both imatinib and sunitinib. They were mixed with 400 mg QD imatinib before the maximum tolerated dose was reached, and/or a single dose of alatinib in combination with imatinib was established. The MTD of alatinib with imatinib was calculated as 350 mg QD by the MTD. In 15 patients, the combination therapy showed partial response in 1 and stable disease. After oral administration in patients with advanced GIST, the MTD of alisib was estimated as 350 mg QD when used in combination with imatinib 400 mg QD.

Source link: https://doi.org/10.1186/s12885-022-09610-4


The efficacy and safety of alpelisib in breast cancer: A real-world analysis

"Published results of alisib + fulvestrant's clinical trials show safety and high incidences of adverse events as a first-line treatment for metastatic breast cancer and as an alternative after cyclin-dependent kinase 4 and 6 inhibitors characterized efficacy and high rates of adverse reactions as a first-line therapeutic breast cancer treatment option. " This is a retrospective cohort review comparing patients with hormone receptor positive, human epidermal growth factor receptor 2 positive metastatic breast cancer who have previously underwent u22642 2 lines of therapy in the metastatic setting and those who have previously undergone u2265 3 lines of therapy in the metastatic setting. In this review, thirty-three patients were included. Patients stopped alisib + fulvestrant due to disease progression, and 27 percent of patients stopped therapy due to adverse effects. This research shows that the results of alisib + fulvestrant were worse in the real-world salvage environment in HR+, HER2-metastastatic breast cancer, as compared to the front-line setting. ".

Source link: https://doi.org/10.1177/10781552221096413


Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

"Abstract Purpose: "Abstract Purpose: In a phase 1b trial, we had previously reported on the effectiveness and the recommended phase 2 dose of olaparib in combination with the PI3K-specific inhibitor alpha1-specific inhibitor algay in patients with high-grade serous ovarian cancer. " Patients and Methods: Eligible patients had recurrent triple-negative breast cancer or recurrent breast cancer of any subtype with a germline BRCA mutation and were enrolled in a dose-escalation or extpansion cohort. Patients with TFx 15% after the first cycle ended had a longer life span than those with TFx u2265 15%. "The results show the possibility of expanding the use of PARP inhibition beyond BRCA-mutant tumors" in the case of potential synergistic use of a PI3K inhibitor to sensitize HR-proficient TNBC to PARP inhibition.

Source link: https://doi.org/10.1158/1078-0432.ccr-21-3045


Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

"Abstract Purpose: PIK3CA mutations are common in breast cancer, and they aid in tumor formation and treatment resistance, according to "Abstract Purpose" (Abrasion). A phase I/III trial of alisib plus nab-paclitaxel in patients with HER2-negative metastatic breast cancer was conducted. Patients and Methods: Patients and Methods: Patients with eligible patients had a HER2-negative MBC before any other chemotherapies. Phase I was a 3+3 dose-escalation plan with three doses of alpaclitaxel 100 mg/m2 administered on days 1, 8, and 15 days a day. Mutations in tumor/circulating tumor DNA were found by PIK3CA mutations. The primary endpoints were recommended phase II dose and objective response rate, according to the primary endpoints. Patients with tumor and/or ctDNA mutation: A total of 40% of patients had an onset of cancer and/or ctDNA mutation; patients with tumor/ctDNA mutation had higher PFS compared to those without mutation. Patients with normal metabolic status had longer PFS in comparison to younger/diabetic patients.

Source link: https://doi.org/10.1158/1078-0432.ccr-20-4879


A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA -Mutated HER2-Positive Metastatic Breast Cancer

"Abstract Purpose: Activating mutations in PIK3CA contribute to resistance to HER2-targeted breast cancer treatment; however, inhibition of PI3K alone leads to escape by feedback upregulation of HER3. Patients and Methods: This phase I review investigated aldab's MTD in patients with a HER2-positive metastatic breast cancer patient in combination with trastuzumab and LJM716 using the continual reassessment technique. Ten patients were hospitalized overnight with alpinisib. Arm A MTD was 250 mg/day. This lead to the opening of arm B, in which 11 patients were intermittently dosed alizab. MTD of alpha alum B 350 mg was administered for 4 days, three days early. MRNA profiling of pre- and on-treatment tissue revealed a PIK3CA target participation by alpharazib induction of downstream signaling and feedback pathways. ".

Source link: https://doi.org/10.1158/1078-0432.ccr-21-0047


FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

"Abstract" means the FDA approved alpelisib in combination with fulvestrant for postmenopause and men with hormone receptor -positive, HER2-negative, phosphatidylinositol-4,5-kinase catalytic subunit alpha -mutated breast cancer in women and men with hormone receptor -negative, phosphatidylinositol-negative, phosphatidylicinol-positive, a -a a phosphate a breast and men and men and men and men and men and men and men and men and metastatic breast cancer, phosphatidyl-mose phosphati phosphatidyl-mona phosphati phosphatiase-monase -negative, phosphatase 3-kinase 3-kinase-monase 3-kinase-negative, phosphatidyl-mosidyl-mata phosphati phosphatas Per RECIST v1. 1 in the cohort of trial participants with a PIK3CA mutation, the primary endpoint was investigator-assessed progression-free survival. The estimated median PFS by investigator estimation in the alisib plus fulvestrant arm was 11 months [95% confidence interval, 7. 5 percent], 6. 5 percent, or 5. 7 months in the placebo plus fulvestrant arm. The median overall survival was not yet reached for the alpha-fulvestrant arm, as well as the full lengthrant control arm's 26. 9. "In trial participants whose tumors did not have a PIK3CA mutation, there was no PFS benefit," the No PFS benefit was observed. ".

Source link: https://doi.org/10.1158/1078-0432.ccr-20-3652

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions